Last quarter (Q4 2023), NovaBay Pharma's total revenue was $3.73M, a decrease of -24.00% from the same quarter last year. In Q4, NovaBay Pharma's net income was $-2.11M. See NovaBay Pharma’s key income statements, including revenue, expenses, profit, and income.

Income Statement	TTM	Dec 23	Dec 22	Dec 21	Dec 20	Dec 19
Total Revenue	$ 14.71M	$ 14.73M	$ 14.40M	$ 368.00K	$ 9.93M	$ 6.60M
Cost of Revenue	$ 4.46M	$ 6.83M	$ 6.62M	$ 3.69M	$ 3.97M	$ 1.74M
Gross Profit	$ 7.89M	$ 7.89M	$ 7.78M	$ -3.69M	$ 5.96M	$ 4.86M
Operating Expense	$ 8.15M	$ 15.49M	$ 22.20M	$ 15.38M	$ 12.39M	$ 14.26M
Operating Income	$ -1.00M	$ -7.60M	$ -14.42M	$ -19.07M	$ -6.43M	$ -9.40M
Net Non Operating Interest Income Expense	-	-	-	-	-	-
Other Income Expense	$ 5.72M	$ 8.85M	$ -5.73M	$ -13.24M	$ -4.61M	$ -252.00K
Pretax Income	$ -16.45M	$ -16.45M	$ -10.61M	$ -5.82M	$ -11.03M	$ -9.65M
Tax Provision	$ 2.00M	-	-	-	$ 5.00K	$ 6.00K
Earnings From Equity Interest Net Of Tax	-	-	-	-	-	-
Net Income Common Stockholders	$ 76.00K	$ -9.64M	$ -16.27M	$ -6.56M	$ -11.04M	$ -10.49M
Basic EPS	$ -3.96	$ -3.96	$ -10.10	$ -5.25	$ -0.31	$ -0.48
Diluted EPS	$ -3.96	$ -3.96	$ -10.10	$ -5.25	$ -0.31	$ -0.48
Basic Average Shares	$ 16.86M	$ 4.21M	$ 1.61M	$ 1.25M	$ 35.08M	$ 21.64M
Diluted Average Shares	$ 15.68M	$ 4.21M	$ 1.61M	$ 1.25M	$ 35.08M	$ 21.64M
Dividend Per Share	-	-	-	-	-	-
Total Operating Income As Reported	-	-	-	-	-	-
Reported Normalized Basic E P S	-	-	-	-	-	-
Reported Normalized Diluted E P S	-	-	-	-	-	-
Rent Expense Supplemental	-	-	-	-	-	-
Total Expenses	$ 12.61M	$ 22.32M	$ 28.82M	$ 19.07M	$ 16.36M	$ 16.00M
Net Income From Continuing And Discontinued Operation	$ 76.00K	$ -9.64M	$ -16.27M	$ -5.82M	$ -11.04M	$ -9.66M
Normalized Income	$ -6.92M	$ -8.30M	$ 6.57M	-	$ -7.23M	$ -10.51M
Interest Expense	-	-	-	-	-	-
EBIT	$ -16.45M	$ -16.45M	$ -10.61M	$ -5.82M	$ -6.43M	$ -9.40M
EBITDA	$ -14.55M	$ -14.55M	$ -10.13M	$ -5.71M	$ -6.38M	$ -9.34M

Currency in USD

NovaBay Pharma Earnings and Revenue History

Get More with TipRanks Premium

What's Included in PREMIUM?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing